Cargando…
Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma
Hypoxia is a predominant feature in glioblastoma (GBM) and contributes greatly to its drug resistance. However, the molecular mechanisms which are responsible for the development of the resistant phenotype of GBM under hypoxic conditions remain unclear. To analyze the key pathways promoting therapy...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367651/ https://www.ncbi.nlm.nih.gov/pubmed/30775317 http://dx.doi.org/10.3389/fonc.2019.00033 |
_version_ | 1783393845449326592 |
---|---|
author | Gao, Yixing Liu, Bao Feng, Lan Sun, Binda He, Shu Yang, Yidong Wu, Gang E, Guoji Liu, Chang Gao, Yuqi Zhang, Erlong Zhu, Bo |
author_facet | Gao, Yixing Liu, Bao Feng, Lan Sun, Binda He, Shu Yang, Yidong Wu, Gang E, Guoji Liu, Chang Gao, Yuqi Zhang, Erlong Zhu, Bo |
author_sort | Gao, Yixing |
collection | PubMed |
description | Hypoxia is a predominant feature in glioblastoma (GBM) and contributes greatly to its drug resistance. However, the molecular mechanisms which are responsible for the development of the resistant phenotype of GBM under hypoxic conditions remain unclear. To analyze the key pathways promoting therapy resistance in hypoxic GBM, we utilized the U87-MG cell line as a human GBM cell model and the human brain HEB cell line as a non-neoplastic brain cell model. These cell lines were cultured in the presence of 21, 5, and 1% O(2) for 24 h. We detected the changes in transcriptional profiling and analyzed the biological processes and functional interactions for the genes with different expression levels under different hypoxia conditions. The results indicated that those alterations of U87-MG cells presented specific transcriptional signature in response to diverse hypoxia levels. Gene ontology analysis revealed that the genes related to the DNA replication and cell cycle were suppressed, while the genes involved in tissue and system development to promote cancer development were activated following hypoxia. Moreover, functional interaction analysis suggested that the epigenetic regulator HDAC3 and the transcriptional factors CEBPB and JUN played a central role in organ and system developmental process pathway. Previous studies reported the global alterations caused by activation of HDAC3, CEBPB, and JUN could form the molecular basis of the resistance to chemotherapy and radiation therapy of hypoxic GBM. In our study, the significant growth inhibitory effect of temozolomide on hypoxic GBM cells could be promoted under downregulation of these genes. The experiment suggested that HDAC3, CEBPB, and JUN were closely involved in the drug-resistance phenotype of hypoxic GBM. In summary, we profiled the hypoxia-dependent changes in the transcriptome of the U87-MG cell line and the human brain cell line HEB to identify the transcriptional signatures of U87-MG cells and elucidate the role of hypoxia in the drug-resistant phenotype of GBM. Furthermore, we identified three key genes and explored their important roles in the drug resistance of hypoxic GBM. |
format | Online Article Text |
id | pubmed-6367651 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63676512019-02-15 Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma Gao, Yixing Liu, Bao Feng, Lan Sun, Binda He, Shu Yang, Yidong Wu, Gang E, Guoji Liu, Chang Gao, Yuqi Zhang, Erlong Zhu, Bo Front Oncol Oncology Hypoxia is a predominant feature in glioblastoma (GBM) and contributes greatly to its drug resistance. However, the molecular mechanisms which are responsible for the development of the resistant phenotype of GBM under hypoxic conditions remain unclear. To analyze the key pathways promoting therapy resistance in hypoxic GBM, we utilized the U87-MG cell line as a human GBM cell model and the human brain HEB cell line as a non-neoplastic brain cell model. These cell lines were cultured in the presence of 21, 5, and 1% O(2) for 24 h. We detected the changes in transcriptional profiling and analyzed the biological processes and functional interactions for the genes with different expression levels under different hypoxia conditions. The results indicated that those alterations of U87-MG cells presented specific transcriptional signature in response to diverse hypoxia levels. Gene ontology analysis revealed that the genes related to the DNA replication and cell cycle were suppressed, while the genes involved in tissue and system development to promote cancer development were activated following hypoxia. Moreover, functional interaction analysis suggested that the epigenetic regulator HDAC3 and the transcriptional factors CEBPB and JUN played a central role in organ and system developmental process pathway. Previous studies reported the global alterations caused by activation of HDAC3, CEBPB, and JUN could form the molecular basis of the resistance to chemotherapy and radiation therapy of hypoxic GBM. In our study, the significant growth inhibitory effect of temozolomide on hypoxic GBM cells could be promoted under downregulation of these genes. The experiment suggested that HDAC3, CEBPB, and JUN were closely involved in the drug-resistance phenotype of hypoxic GBM. In summary, we profiled the hypoxia-dependent changes in the transcriptome of the U87-MG cell line and the human brain cell line HEB to identify the transcriptional signatures of U87-MG cells and elucidate the role of hypoxia in the drug-resistant phenotype of GBM. Furthermore, we identified three key genes and explored their important roles in the drug resistance of hypoxic GBM. Frontiers Media S.A. 2019-02-01 /pmc/articles/PMC6367651/ /pubmed/30775317 http://dx.doi.org/10.3389/fonc.2019.00033 Text en Copyright © 2019 Gao, Liu, Feng, Sun, He, Yang, Wu, E, Liu, Gao, Zhang and Zhu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Gao, Yixing Liu, Bao Feng, Lan Sun, Binda He, Shu Yang, Yidong Wu, Gang E, Guoji Liu, Chang Gao, Yuqi Zhang, Erlong Zhu, Bo Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma |
title | Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma |
title_full | Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma |
title_fullStr | Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma |
title_full_unstemmed | Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma |
title_short | Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma |
title_sort | targeting jun, cebpb, and hdac3: a novel strategy to overcome drug resistance in hypoxic glioblastoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367651/ https://www.ncbi.nlm.nih.gov/pubmed/30775317 http://dx.doi.org/10.3389/fonc.2019.00033 |
work_keys_str_mv | AT gaoyixing targetingjuncebpbandhdac3anovelstrategytoovercomedrugresistanceinhypoxicglioblastoma AT liubao targetingjuncebpbandhdac3anovelstrategytoovercomedrugresistanceinhypoxicglioblastoma AT fenglan targetingjuncebpbandhdac3anovelstrategytoovercomedrugresistanceinhypoxicglioblastoma AT sunbinda targetingjuncebpbandhdac3anovelstrategytoovercomedrugresistanceinhypoxicglioblastoma AT heshu targetingjuncebpbandhdac3anovelstrategytoovercomedrugresistanceinhypoxicglioblastoma AT yangyidong targetingjuncebpbandhdac3anovelstrategytoovercomedrugresistanceinhypoxicglioblastoma AT wugang targetingjuncebpbandhdac3anovelstrategytoovercomedrugresistanceinhypoxicglioblastoma AT eguoji targetingjuncebpbandhdac3anovelstrategytoovercomedrugresistanceinhypoxicglioblastoma AT liuchang targetingjuncebpbandhdac3anovelstrategytoovercomedrugresistanceinhypoxicglioblastoma AT gaoyuqi targetingjuncebpbandhdac3anovelstrategytoovercomedrugresistanceinhypoxicglioblastoma AT zhangerlong targetingjuncebpbandhdac3anovelstrategytoovercomedrugresistanceinhypoxicglioblastoma AT zhubo targetingjuncebpbandhdac3anovelstrategytoovercomedrugresistanceinhypoxicglioblastoma |